XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.3Close
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
 [1]
Assets    
Cash and cash equivalents $ 8,497 $ 5,924
Investments 1,046 905
Accounts receivable, net 19,083 17,218
Inventories 4,416 4,777
Other current assets 1,476 1,298
Total current assets 34,518 30,122
Long-term investments 18,974 16,288
Reinsurance recoverables 4,920 5,416
Property and equipment 3,924 3,774
Goodwill 45,810 45,811
Other intangible assets 31,324 32,492
Other assets 3,147 2,704
Separate account assets 7,028 7,278
TOTAL ASSETS 149,645 143,885 Close
Liabilities    
Current insurance and contractholder liabilities 7,352 5,409
Pharmacy and other service costs payable 19,320 17,070
Accounts payable 7,673 7,775
Accrued expenses and other liabilities 9,668 7,978
Short-term debt 3,046 2,993
Total current liabilities 47,059 41,225
Non-current insurance and contractholder liabilities 11,286 11,976
Deferred tax liabilities, net 7,480 7,786
Other non-current liabilities 2,932 2,766
Long-term debt 28,094 28,100
Separate account liabilities 7,028 7,278
TOTAL LIABILITIES 103,879 99,131 Close
Contingencies — Note 16
Redeemable noncontrolling interests 64 66 Close
Shareholders' equity    
Common stock [2] 4 4
Additional paid-in capital 30,563 30,233
Accumulated other comprehensive loss (2,119) (1,658)
Retained earnings 40,982 37,940
Less: Treasury stock, at cost (23,739) (21,844)
TOTAL SHAREHOLDERS' EQUITY 45,691 44,675
Other noncontrolling interests 11 13
Total equity 45,702 44,688 Close
Total liabilities and equity $ 149,645 $ 143,885
[1] Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.
[2] Par value per share, $0.01; shares issued, 399 million as of September 30, 2023 and 398 million as of December 31, 2022; authorized shares, 600 million.